FGFR-driven diseases go beyond the diagnosis,
Pursuing a selective path
Cholangiocarcinoma and further research
For first-line treatment of cholangiocarcinoma
QED Therapeutics Presents New Data on the Potential for Infigratinib to Treat Upper Tract Urothelial Carcinoma
Preclinical Data Demonstrates the Potential of QED Therapeutics’ Infigratinib in Multiple FGFR+ Tumor Types
QED Therapeutics Announces a Collaboration with Foundation Medicine to Develop Companion Diagnostics for Infigratinib
Receive updates on the development of infigratinib and breaking news from QED Therapeutics.
75 Federal Street
San Francisco, CA 94107
By selecting “Proceed” you will leave QEDTx.com and be directed to an external website.